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Abstract. One of the reasons for worsening the epidemiological
situation is the change of biological properties of bacilli, the failure
of the first and the second courses of chemotherapy, interrupted
treatment, relapse tuberculosis (TB), unadequit treatment, contact
with patients drug resistant tuberculosis insufficient effectiveness of
existing TB drugs [3,7 ].  Production of IL-6 and IL-10 in TB patients
is independent of drug resistance, but increases in response to
increased synthesis of endotoxins by MBT; the magnitude of endo-
genous intoxication and cytotoxic hypoxia creates prerequisites for
the development of drug resistant strains. The IL-18/IL-10 ratio in
these patients characterizes the increase in severity of the patient's
state, the spread of inflammation processes in the lungs and the
development of drug resistance; there is a significant bulk of the Tx-
lymphocyte type 2 (CD4+), which indicates the development of deep
gap in cell-mediated immune response and prevalence of an inef-
fective anti-inflammation immune activation.
Keywords: tuberculosis, multidrug-
resistant, interleukins.
Introduction
According to WHO Ukraine ranks 1-st in the
ratio multidrug-resistant tuberculosis (MDRTB)
among patients receiving re-treatment (79.4 %) [7].
In Ukraine MDRTB diagnosed in 16 % of patients
who first diagnosed TB and 44 % of patients with
recurrent disease. In October 2013 surveillance
WHO stated that all new TB cases in the world is
3.6 % MDRTB; 9.6 % (8,1-11,2 %) of all cases re-
gistered MDRTB - extensively drug resistant TB
(XDR). 60.0 % of the world's MDRTB established in
Brazil, China, India and South Africa [1, 3, 7].
Drug resistant TB - is the form in which the pa-
tient identifies Mycobacterium tuberculosis resistant
to one or more anti-TB-drugs, as confirmed by a
laboratory test drug susceptibility [3]. In patients with
pulmonary TB drug resistance reaches 81 % [2].
Among the varieties the most concern is the stability
MDRTB that may be the cause of XDR.
It remains unclear the role of cytokines in the
development of resistance of mycobacteria to anti-
TB-drugs. Also, are not yet identified markers that
reflect the progression of pathological process in
multidrug-resistant tuberculosis, and was not set their
predictive role in assessing the success of anti-
tuberculosis chemotherapy in standardized programs
[4, 5, 6].
Aim
Determine the features of cytokine regulation in
patients with multidrug-resistant pulmonary tuber-
culosis and their role in development of the systemic
inflammatory response.
Material and methods
Were enrolled 116 patients with pulmonary TB.
All subjects were randomized in 3 study cohorts: co-
hort 1 (41 subjects) were included patients with new-
ly diagnosed pulmonary TB, with preserved sen-
sibility to TB drugs; cohort 2 (63 subjects) were inc-
luded MDR TB patients with confirmed resistance
to at least 3 first line TB drugs (HRS), cohort 3 (12
subjects) were included patients with XDR TB,
control group (20 subjects) were included healthy
humans Clinical, radiological, biochemical, micros-
copic, microbiological, immune-enzymatic and statis-
tical study (ANOVA and Pearson correlation) me-
thods were used.
Discussion of the study
We carried out a comparative analysis of certain
pro- and anti-inflammatory cytokines (Table) that
shows a significant increase in the plasma con-
centration of cytokines in TB groups vs. control
group, and we determined the probability of the de-
pendence of these parameters upon the resistance
profile of the MBT. So, the blood concentrations of
IL-6 in all groups TB groups were significantly
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increased compared to control group, there was a
11.08 fold increase in group 1, 13.9 fold increase in
group 2, and 4 fold increase in group 3 of IL-6 level
(p<0.001). A significant intergroup difference was
found of plasma concentration of IL-6 between pa-
tients with sensitive and resistant TB (Table). Thus,
the level of IL-6 in group 2 was 1.7 fold increased,
compared to group1 (p
1
<0.01). However, in patients
of group 3 marked reduction in IL-6 concentration
was compared to group1 - 2.8 fold (p<0.001) and
group 2 - 3.5 fold (p
3
<0.001). Low values of IL-6 in
patients XDR TB, in our opinion, can lead to chronic
carrier of intracellular infection, rapidly progressive
course of the inflammatory process, which poorly
responds to anti-TB treatment and, probably, is one
of the factors producing their own XDR TB forms
due to prevalence of humoral immune responses [2,
3, 5].
A pronounced activation of all phases of the inf-
lammatory niprocess in all study cohorts compared
to control group, probably, is indicated by the increa-
se in the level of anti-inflammatory IL-10 (Table 1).
Thus, in group 1 level of IL-10 increased by 2.3 folds,
in group 2 - 1.8 folds, in group 3 - by 1.9 folds
(p<0.001), this indicate on inhibition of cellular immu-
nity and perhaps the beginning of specific chronic
inflammatory process. The plasma concentration of
IL-10 in sensitive TB patients has increased by 1.2
folds compared to group 2 and 3 (p1<0.001,
p
2
<0.01). There were no statistically significant diffe-
rences in concentration of IL-10 in group 2 and 3
(p
3
>0.4).
The activity of IL-18, whose role is to improve
the resistance to intracellular pathogens and is essen-
Òàble
Plasma concentrations of certain cytokines in sensitive and resistant pulmonary
tuberculosis patients
Cytokines Control group 
(n=20) 
Group 1 
(n=41) 
Group 2 
(n=63) 
Group 3 
(n=12) 
IL-6* 
(pg/ml) 
1.708±0.015 18.92±14.17 
р<0.001 
23.70±13.39 
р<0.001 
р1<0.01 
6.84±5.4 
р<0.001 
р2<0.01 
р3<0.001 
IL-10 
(pg/ml) 
1.79±0.127 4.2±0.75 
р<0.05 
3.38±0.79 
р<0.001 
р1>0.001 
3.55±0.23 
р<0.001 
р2<0.01 
р3>0.4 
IL-18 
(pg/ml) 
268.34±101.74 537.67±276.67 
р<0.001 
329.32±148.10 
р<0.1 
р1<0.001 
194.11±81.89 
р<0.05 
р2<0.001 
р3>0.05 
Note: Data are presented as average and standard error (M±m). p – significance level related to control group;
p1 – significance level between group 1 and 2; p2 – significance level between group 1 and 3; p3 – significance
level between group 2 and 3. * – interleukine 
 tial for the formation of anti-TB acquired immunity,
significantly increased in sensitive and MDRTB pa-
tients compared to control group. For example, in
gropu1 there is a 2 fold IL-18 increase (p<0.001),
respectively, in group 2 - 1.2 fold (p<0.1). However,
in patients XDR TB there is a tendency to reduce the
plasma concentration of this cytokine below the level
of control group. The level of IL-18 in group 3 dec-
reased by 1.4 folds in comparison with control group
(p<0.05) (Fig.). Intergroup difference of plasma con-
centration of IL-18 in sensitive and MDR TB pa-
tients was proved. Thus, in group 2 vs. group 1 there
is a 1.6 folds decrease of IL-18 (p
1
<0.001), IL-18
decrease in group 3 vs. group 1 was of 2.7 folds
(p
2
<0.001). Also, there is a decrease of IL-18 con-
centration in group 3 of 1.7 folds compared to group
2 (p
3
<0.05). The difference in plasma concentration
Fig. 1 Changes in the level of pro- and anti-
inflammatory cytokines (pg/ml) in sensitive and
MDR TB
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of IL-18 in sensitive and MDRTB patients is on the
ultimate level of statistical significance (p
1,2
<0.001).
Discussion  In our opinion, the production of IL-6
and IL-10 in TB patients, regardless of resistance,
raise in response to increased synthesis of MBT en-
dotoxins, increase of endogenous intoxication and
cytotoxic hypoxia, all these create prerequisites for
the development of resistance. What caused the lack
of correlation between the IL is not yet clear, ho-
wever, this fact is not crucial, as the most important
prognostic criterion is the imbalance in the IL-18/IL-
10 ratio; with an increase in the severity of the pa-
tient's condition, the spread of inflammation proce-
sses in the lungs and the development of drug resis-
tance; there is a significant bulk of the Tx-lym-
phocyte type 2 (CD4+), which indicates the deve-
lopment of deep gap in cellmediated immune res-
ponse and prevalence of an ineffective anti-inflam-
mation immune activation. The increase in IL-6
plasma concentration, probably, indicates a high
activity of systemic inflammatory response, which is
maximally expressed in MDRTB patients (23.70±
13.39). This cytokine plays a key role in the deve-
lopment of inflam mation, immune response to
infectious factor and lung tissue damage with the
formation of massive destructive changes that were
present in patients groups assessed by us. IL-6 plays
a special role as "hepatocyte activating factor",
which induce the synthesis of acute-phase proteins in
the framework of systemic inflammatory response
that leads to emerge of specific inflammation process
outside the pulmonary tissue and activation of sys-
temic inflammatory response syndrome.
High levels of IL-10 in patients with pulmonary
TB have a favorable prognostic impact, because
multifunctional properties of IL-10, ability to inhibit
the synthesis of most proinflammatory cytokines and
block apoptosis of macrophages and monocytes play
an important role in the formation of a limited spe-
cific inflammation in the broncho-pulmonary paren-
chyma. Given the fact, those in MDR TB and XDR
TB patients' levels of IL-10 is not too high and are
efinitely lower than in newly diagnose TB patients, in
such patients widespread, disseminated TB forms
dominate over infiltrative forms (ratio 1:2).
Conclusions
1.Assessment of IL-6 plasma concentration in
pulmonary MDR TB vs. sensible TB patients re-
vealed a significant 1.7 folds increase (p
1
<0.01), and,
respectively, a significant 1.2 folds decrease in the
level of IL-10 and IL-18 (p
1
<0.001), these confirm
the strengthening of endogenous intoxication, cytoto-
xic hypoxia and activation "systemic inflammatory
response" syndrome.
2.Assessment of plasma concentration of certain
pro- andanti-inflammatory cytokines in MDRTB pa-
tients showed that it is dependent on the profile of
MBT resistance to anti-TB drugs. Plasma concent-
ration of IL-10 in MDR and XDR TB patients is
significant lower than in sensible TB patients and
correlates with the prevalence in MDRTB patients of
widespread/disseminate TB forms over infiltrative
TB forms (1:2 ratio).
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ÏÎÊÀÇÍÈÊÈ ÖÈÒÎÊ²ÍÎÂÎ¯ ÐÅÃÓËßÖ²¯ Ó ÕÂÎÐÈÕ
Ç ÌÓËÜÒÈÐÅÇÈÑÒÅÍÒÍÈÌ ÒÓÁÅÐÊÓËÜÎÇÎÌ
ËÅÃÅÍÜ
².Â. ªðåìåí÷óê, Ë.Ä. Òîäîð³êî, Â.². Ñëèâêà, Ò.². ²ëü÷èøèí
Ðåçþìå. Îäí³ºþ ç ïðè÷èí ïîã³ðøåííÿ åï³äåì³îëîã³÷íî¿
ñèòóàö³¿ º çì³íà á³îëîã³÷íèõ âëàñòèâîñòåé ì³êîáàêòåð³é,
íåâäà÷à ïåðøîãî òà ïîâòîðíîãî êóðñ³â õ³ì³îòåðàï³¿, ïåðåð-
âàíå ë³êóâàííÿ, ðåöèäèâ òóáåðêóëüîçó (ÒÁ), áåçóñï³øíå
ë³êóâàííÿ, êîíòàêò ç õâîðèì íà ÕÐÒÁ, íåäîñòàòíÿ åôåê-
òèâí³ñòü ³ñíóþ÷èõ ïðîòèòóáåðêóëüîçíèõ ïðåïàðàò³â.
Ïðîäóêö³ÿ ²Ë-6 òà ²Ë-10 ó ãðóïàõ õâîðèõ íà ÒÁ íåçà-
ëåæíî â³ä ðåçèñòåíòíîñò³ çðîñòàº ó â³äïîâ³äü íà ï³äâèùåííÿ
ñèíòåçó åíäîòîêñèí³â ÌÁÒ ³ íàðîñòàííÿ åíäîãåííî¿ ³í-
òîêñèêàö³¿ òà öèòîòîêñè÷íî¿ ã³ïîêñ³¿, ùî ñòâîðþº ïåðåäóìîâè
äëÿ ðîçâèòêó ¿õ ðåçèñòåíòíîñò³. Äèñáàëàíñ ñï³ââ³äíîøåííÿ
²Ë-18/²Ë-10 ó öèõ õâîðèõ õàðàêòåðèçóº íàðîñòàííÿ òÿæêîñò³
ñòàíó ïàö³ºíòà, ïîøèðåí³ñòü çàïàëüíîãî ïðîöåñó â ëåãåíÿõ ³
ôîðìóâàííÿ ðåçèñòåíòíîñò³; â³äçíà÷àºòüñÿ ³ñòîòíà ïåðåâàãà
ë³ìôîöèò³â Òõ-2 òèïó (CD4+), ùî âêàçóº íà ðîçâèòîê
ãëèáîêîãî äåôåêòó êë³òèííî-îïîñåðåäêîâàíîãî ³ìóííîãî
çàõèñòó é ïåðåâàãó ïðîòèçàïàëüíî¿ ³ìóííî¿ àêòèâàö³¿.
Êëþ÷îâ³ ñëîâà: òóáåðêóëüîç, ìóëüòèðåçèñòåíòíèé
òóáåðêóëüîç ëåãåíü, ³íòåðëåéê³íè.
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ÁÎËÜÍÛÕ Ñ ÌÓËÜÒÈÐÅÇÈÑÒÅÍÒÍÛÌ
ÒÓÁÅÐÊÓËÅÇÎÌ ËÅÃÊÈÕ
È.Â. Åðåìåí÷óê, Ë.Ä. Òîäîðèêî, Â.È. Cëûâêà,
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Ðåçþìå. Îäíîé èç ïðè÷èí óõóäøåíèÿ ýïèäåìèî-
ëîãè÷åñêîé ñèòóàöèè ÿâëÿåòñÿ èçìåíåíèå áèîëîãè÷åñêèõ
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ñâîéñòâ ìèêîáàêòåðèé, íåóäà÷à ïåðâîãî è ïîâòîðíîãî êóðñîâ
õèìèîòåðàïèè, ïðåðâàííîå ëå÷åíèå, ðåöèäèâ òóáåðêóëåçà
(ÒÁ), áåçóñïåøíîå ëå÷åíèå, êîíòàêò ñ áîëüíûì ÕÐÒÁ,
íåäîñòàòî÷íàÿ ýôôåêòèâíîñòü ñóùåñòâóþùèõ ïðîòèâîòó-
áåðêóëåçíûõ ïðåïàðàòîâ.
Ïðîäóêöèÿ ÈË-6 è ÈË-10 â ãðóïïàõ áîëüíûõ ÒÁ
íåçàâèñèìî îò ðåçèñòåíòíîñòè âîçðàñòàåò â îòâåò íà ïîâû-
øåíèå ñèíòåçà ýíäîòîêñèíîâ ÌÁÒ è íàðàñòàíèå ýíäîãåííîé
èíòîêñèêàöèè è öèòîòîêñè÷åñêîé ãèïîêñèè, ÷òî ñîçäàåò
ïðåäïîñûëêè äëÿ ðàçâèòèÿ èõ ðåçèñòåíòíîñòè. Äèñáàëàíñ
ñîîòíîøåíèÿ ÈË-18/ÈË-10 ó ýòèõ áîëüíûõ õàðàêòåðèçóåò
íàðàñòàíèå òÿæåñòè ñîñòîÿíèÿ ïàöèåíòà, ðàñïðîñòðàíåííîñòü
âîñïàëèòåëüíîãî ïðîöåññà â ëåãêèõ è ôîðìèðîâàíèå ðåçèñ-
òåíòíîñòè; îòìå÷àåòñÿ ñóùåñòâåííîå ïðåèìóùåñòâî ëèì-
ôîöèòîâ Òõ-2 òèïà (CD4+), ÷òî óêàçûâàåò íà ðàçâèòèå
ãëóáîêîãî äåôåêòà êëåòî÷íî-îïîñðåäîâàííîé èììóííîé
çàùèòû è ïðåèìóùåñòâî ïðîòèâîâîñïàëèòåëüíîé èììóííîé
àêòèâàöèè.
Êëþ÷åâûå ñëîâà: òóáåðêóëåç, ìóëüòèðåçèñòåíòíûé
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